SCHEMBL3285533

SCHEMBL3285533

COc1ccc(CNc2nc(NCCOC(C)NC(=O)OC(C)(C)C)nc(NCc3ccc(OC)cc3)n2)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.43
PPARG P37231 1/20 0.43
PPARA Q07869 1/20 0.43
LMNA P02545 1/20 0.43
VNN1 O95497 2/20 0.41
CCNE2 O96020 2/20 0.41
CCNE1 P24864 2/20 0.41
CDK2 P24941 2/20 0.41
HSP90AA1 P07900 1/20 0.40
GAA P10253 1/20 0.40
CCNA2 P20248 1/20 0.40
CCNA1 P78396 1/20 0.40
ACACB O00763 1/20 0.40
KDM4E B2RXH2 1/20 0.39
HPGD P15428 1/20 0.39
ABCB1 P08183 1/20 0.39
CACNA1B Q00975 1/20 0.39
ITGB3 P05106 1/20 0.39
ITGA2B P08514 1/20 0.39
TP53 P04637 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3285536 0.83 ADORA2A (0.46) ALDH1A1VNN1HSP90AA1GAAKDM4E
SCHEMBL13326022 0.82 ADORA2A (0.47) ALDH1A1VNN1HSP90AA1GAA
SCHEMBL12203612 0.71 ACACB (0.58) ALDH1A1PPARGPPARALMNAACACB
SCHEMBL8732751 0.71 ACACB (0.58) ALDH1A1PPARGPPARALMNAACACB
SCHEMBL7652554 0.71 NPC1 (0.58) ALDH1A1LMNAGAAHPGDMAPT
SCHEMBL10276786 0.71 CA2 (0.55) ALDH1A1LMNA
SCHEMBL10276787 0.71 CA2 (0.55) ALDH1A1LMNA
SCHEMBL3120956 0.70 CTNNB1 (0.51) CCNE2CCNE1CDK2KDM4E
SCHEMBL1673449 0.70 ABCB1 (0.47) ALDH1A1PPARGPPARALMNAGAA
SCHEMBL2843448 0.70 L3MBTL1 (0.46) LMNAVNN1GAAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7718655-B2 Trisubstituted triazine compounds, and methods for making and using the compounds, which have antitubulin activity NEW YORK UNIVERSITY (US) 2010-05-18 US disclosed
US-20040122009-A1 Trisubstituted triazine compounds, and methods for making and using the compounds, which have antitubulin activity NEW YORK UNIVERSITY (US) 2004-06-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040122009-A1 Trisubstituted triazine compounds, and methods for making and using the compounds, which have antitubulin activity TUBA1C, TUBB1, TUBB ALDH1A1 3453/4885PPARG 3670/4885PPARA 4352/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.